[Jmol-users] corporate endorsement of Jmol

[Miguel <mi...@jm...>]

Warren wrote:
> Miguel is right that companies can sometimes be sensitive to this
> information, especially early on.  However, every company that makes an=

> investment in deploying Jmol has a shared interest in seeing the projec=
t
> succeed.

I couldn't agree more.

> Thus, if asked nicely, I bet that such case studies &
> endorsements could be obtained.

The only way that I know that people are using Jmol is via jmol-users.

> Another high-impact approach would be to prepare some real world exampl=
es
> online.  The demonstration page is a great start, but to the extent tha=
t
> we
> seek corporate adoption (to make Jmol economically self-sufficent), it =
is
> hard to imagine something more powerful than a publicly-accessible Jmol=

> web
> page with drug-discovery content.  This would paint an indelible pictur=
e
> in
> the minds of your potential customers as to what Jmol would look like w=
ith
> their own proprietary molecules.

Understood.

> Jmol may be a feature or two shy of having all the features necessary t=
o
> support such usage, but as soon as solid surfaces are implemented, I wo=
uld
> happily contribute some examples.

I am working on surfaces. Am struggling with some things. Warren, I may
call you next week to discuss on the phone.

> Loading multiple molecules with a
> shared
> frame of reference will be essential for this.

No work has yet begun in this area.

> PS.  My article =22The Case for Open-Source Software in Drug Discovery=22=
 was
> published in Drug Discovery Today, *today*=21  It is not yet avaiable o=
nline
> AFAIK, but I can forward a copy to interested parties upon request.

Congratulations=21



Miguel